Drug Interactions between Ferrex 150 Plus and Hyperhep B
This report displays the potential drug interactions for the following 2 drugs:
- Ferrex 150 Plus (ascorbic acid/iron polysaccharide)
- Hyperhep B (hepatitis b immune globulin)
Interactions between your drugs
No interactions were found between Ferrex 150 Plus and Hyperhep B. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Ferrex 150 Plus
A total of 114 drugs are known to interact with Ferrex 150 Plus.
- Ferrex 150 plus is in the following drug classes: iron products, vitamin and mineral combinations.
- Ferrex 150 plus is used to treat Dietary Supplementation.
Hyperhep B
A total of 22 drugs are known to interact with Hyperhep B.
- Hyperhep b is in the drug class immune globulins.
- Hyperhep b is used to treat Exposure to Hepatitis B Virus.
Drug and food interactions
iron polysaccharide food
Applies to: Ferrex 150 Plus (ascorbic acid/iron polysaccharide)
ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.
Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham PROD
- "Product Information. Accrufer (ferric maltol)." Shield Therapeutics (2021):
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.